These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 38548262)

  • 21. High incidence of drug-resistant Mycobacterium tuberculosis in Hainan Island, China.
    Lin M; Zhong Y; Chen Z; Lin C; Pei H; Shu W; Pang Y
    Trop Med Int Health; 2019 Sep; 24(9):1098-1103. PubMed ID: 31278806
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthetic investigational new drugs for the treatment of tuberculosis.
    Kwon YS; Koh WJ
    Expert Opin Investig Drugs; 2016; 25(2):183-93. PubMed ID: 26576631
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multidrug-resistant tuberculosis of the spine--is it the beginning of the end? A study of twenty-five culture proven multidrug-resistant tuberculosis spine patients.
    Pawar UM; Kundnani V; Agashe V; Nene A; Nene A
    Spine (Phila Pa 1976); 2009 Oct; 34(22):E806-10. PubMed ID: 19829244
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multidrug-resistant tuberculosis.
    Wulandari DA; Hartati YW; Ibrahim AU; Pitaloka DAE; Irkham
    Clin Chim Acta; 2024 Jun; 559():119701. PubMed ID: 38697459
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New antituberculous drugs in development.
    Lalloo UG; Ambaram A
    Curr HIV/AIDS Rep; 2010 Aug; 7(3):143-51. PubMed ID: 20559756
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antitubercular activity of disulfiram, an antialcoholism drug, against multidrug- and extensively drug-resistant Mycobacterium tuberculosis isolates.
    Horita Y; Takii T; Yagi T; Ogawa K; Fujiwara N; Inagaki E; Kremer L; Sato Y; Kuroishi R; Lee Y; Makino T; Mizukami H; Hasegawa T; Yamamoto R; Onozaki K
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4140-5. PubMed ID: 22615274
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Underestimated pyrazinamide resistance may compromise outcomes of pyrazinamide containing regimens for treatment of drug susceptible and multi-drug-resistant tuberculosis in Tanzania.
    Juma SP; Maro A; Pholwat S; Mpagama SG; Gratz J; Liyoyo A; Houpt ER; Kibiki GS; Mmbaga BT; Heysell SK
    BMC Infect Dis; 2019 Feb; 19(1):129. PubMed ID: 30732572
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Opportunities for overcoming tuberculosis: Emerging targets and their inhibitors.
    Yang L; Hu X; Chai X; Ye Q; Pang J; Li D; Hou T
    Drug Discov Today; 2022 Jan; 27(1):326-336. PubMed ID: 34537334
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An update on multidrug-resistant tuberculosis .
    Park M; Satta G; Kon OM
    Clin Med (Lond); 2019 Mar; 19(2):135-139. PubMed ID: 30872297
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis and bioactivity of antitubercular peptides and peptidomimetics: an update.
    De Leon Rodriguez LM; Kaur H; Brimble MA
    Org Biomol Chem; 2016 Jan; 14(4):1177-87. PubMed ID: 26645944
    [TBL] [Abstract][Full Text] [Related]  

  • 31. DFT based QSAR/QSPR models in the development of novel anti-tuberculosis drugs targeting Mycobacterium tuberculosis.
    Rajkhowa S; Deka RC
    Curr Pharm Des; 2014; 20(27):4455-73. PubMed ID: 24245759
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vitamin C Potentiates the Killing of Mycobacterium tuberculosis by the First-Line Tuberculosis Drugs Isoniazid and Rifampin in Mice.
    Vilchèze C; Kim J; Jacobs WR
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29298757
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Management of multidrug-resistant tuberculosis].
    Tritar F; Daghfous H; Ben Saad S; Slim-Saidi L
    Rev Pneumol Clin; 2015; 71(2-3):130-9. PubMed ID: 25153927
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug-resistant tuberculosis: pediatric guidelines.
    Al-Dabbagh M; Lapphra K; McGloin R; Inrig K; Schaaf HS; Marais BJ; Sauve L; Kitai I; Kollmann TR
    Pediatr Infect Dis J; 2011 Jun; 30(6):501-5. PubMed ID: 21297522
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clofazimine: A useful antibiotic for drug-resistant tuberculosis.
    Mirnejad R; Asadi A; Khoshnood S; Mirzaei H; Heidary M; Fattorini L; Ghodousi A; Darban-Sarokhalil D
    Biomed Pharmacother; 2018 Sep; 105():1353-1359. PubMed ID: 30021373
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recent advances in the diagnosis and treatment of multidrug-resistant tuberculosis.
    Ahmad S; Mokaddas E
    Respir Med; 2009 Dec; 103(12):1777-90. PubMed ID: 19660927
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The potential role of trimethoprim-sulfamethoxazole in the treatment of drug-resistant tuberculosis.
    Palomino JC; Martin A
    Future Microbiol; 2016; 11(4):539-47. PubMed ID: 27070731
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of New Therapeutics to Meet the Current Challenge of Drug Resistant Tuberculosis.
    Sheikh BA; Bhat BA; Mehraj U; Mir W; Hamadani S; Mir MA
    Curr Pharm Biotechnol; 2021; 22(4):480-500. PubMed ID: 32600226
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recent advances for identification of new scaffolds and drug targets for Mycobacterium tuberculosis.
    Dhiman R; Singh R
    IUBMB Life; 2018 Sep; 70(9):905-916. PubMed ID: 29761628
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lessons learned from treating drug-resistant TB and how to apply these to drug-susceptible TB.
    Godefroy N; Monsel G; Jauréguiberry S; Henry B; Véziris N; Aubry A; Robert J; Jachym M; Caumes E; Pourcher V
    Int J Tuberc Lung Dis; 2024 Jul; 28(7):357-359. PubMed ID: 38961549
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.